(OP:FTHWF)

N/A UNCHANGED

Last Price Updated: 3:57 PM EDT, Mar 21, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about FTHWF

Reunion Neuroscience On The Brink Of Going Private With Final Court Approval ↗

July 17, 2023

Clinical-stage psychedelics company Reunion Neuroscience (NASDAQ: REUN) is about to close on its take-private transaction with MPM BioImpact affiliates, as shareholders voted for a special resolution...

Via Benzinga

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

Ketamine News: PharmaTher Begins FDA Filing For KETARX Application, Stella Acquires Field Trip Assets ↗

June 27, 2023

Specialty biotech company PharmaTher Holdings Ltd. (OTCQB: PHRRF) has filed a pre-submission facility correspondence in advance of its Abbreviated New Drug Application (ANDA) for its novel racemic...

Via Benzinga

Can Field Trip Health & Wellness Re-Emerge From Creditor Protection? What The CCAA Data Shows ↗

March 27, 2023

Potentially, a significant business casualty has befallen the psychedelic sector.

Via Benzinga

Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗

March 20, 2023

Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered

Via Benzinga

In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend? ↗

March 15, 2023

Closely following the announcement of what's to become of the new regulations for telehealth, including ketamine therapy, several of in-clinic treatment centers have announced they are closing their...

Via Benzinga

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

Field Trip H&W Closes Q3 2023 On Material Uncertainty, Need To Lower Costs & Adapt To New Regulations ↗

March 01, 2023

Ketamine therapy provider Field Trip Health & Wellness Ltd. (OTCQB: FTHWF) shared its Q3 2023 results for three and nine months ended Dec. 31, 2022 and some of the period’s highlights. Financials:

Via Benzinga

'Sea Change': Irwin Naturals, Numinus And Field Trip Discuss Psychedelics At Cantor Webinar ↗

February 03, 2023

Cantor Fitzgerald's Pablo Zuanic hosted a virtual panel discussion about the psychedelics industry with three ketamine therapy providers: Irwin Naturals (OTCMKTS: IWINF)’ CEO Klee Irwin, Field Trip H&W...

Via Benzinga

Irwin Naturals, Numinus, Field Trip: Sector Analyst Compares Footprints, Cash, Organic Growth ↗

January 24, 2023

The Analyst

Via Benzinga

Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month ↗

December 25, 2022

Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the...

Via Talk Markets

KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing

December 16, 2022

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Field Trip Health Ltd. (OTC: FTHWF) (TSX.V: FTHW) Featured in Virtual Coverage of the KCSA Mental Health Investor Conference

December 13, 2022

Via Investor Brand Network

KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th

December 13, 2022

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com

From Virtual Investor Conferences

Via GlobeNewswire

Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD ↗

December 11, 2022

Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances.

Via Talk Markets

Psychedelic Drug Stocks Index Has A Good Week ↗

November 27, 2022

We track six psychedelic stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances.

Via Talk Markets

These Are The Top Companies And Most Influential People In The Psychedelics Space: Meet The Winners Of The Microdose Awards ↗

November 07, 2022

Which are the top companies and who are the most influential people in the psychedelics space? According to Microdose Psychedelic Insights, host of the Microdose Awards, these are the ones to watch.

Via Benzinga

15 Global Psychedelics Executives To Keep An Eye On In 2022 ↗

October 28, 2022

As the global psychedelics industry booms, with companies going public, major financings being announced, and celebrities and big investors getting on board, Benzinga has decided to put together a list...

Via Benzinga

What Are The Best Psychedelic-Assisted Therapy Clinics In The World? Here Are 5 To Check Out ↗

October 28, 2022

Psychedelic-Assisted Therapy, or PAT, is the type of treatment in which the delivery of a psychedelic substance -i.e.

Via Benzinga

Psychedelic Drug Stocks Index Up Slightly This Week ↗

October 08, 2022

There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD.

Via Talk Markets

Psychedelic Stocks Continue To Plummet: -16% This Week; -33% MTD; Now -57% YTD ↗

September 25, 2022

Look at how the only psychedelic stocks with market caps larger than $50M gave performed this last week.

Via Talk Markets

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.